The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea

May 3, 2006International journal of obesity (2005)

Sibutramine-assisted weight loss in men with obstructive sleep apnea

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Eighty-seven obese men with obstructive sleep apnoea lost an average of 8.3 kg over six months in a sibutramine-assisted weight loss program.

Weight loss is associated with a significant reduction in waist and neck circumference, as well as sagittal height.
The severity of obstructive sleep apnoea improved, with a decrease of 16.3 events per hour in the respiratory disturbance index.
The Epworth sleepiness score, indicating daytime sleepiness, decreased by 4.5 points.
No significant changes were observed in systolic or diastolic blood pressure.
A mild increase in resting heart rate was noted.

AI simplified

OBJECTIVE: Obstructive sleep apnoea (OSA) occurs frequently in obese patients and may be reversible with weight loss. Obstructive sleep apnoea and obesity are both independent risk factors for hypertension and increased sympathetic activity. Sibutramine has been increasingly used in the management of obesity, but is relatively contraindicated in patients with hypertension. No studies have investigated the effect of sibutramine on OSA, blood pressure and heart rate. We aimed to assess the changes in OSA and cardiovascular parameters in obese men with OSA enrolled in a sibutramine-assisted weight loss programme (SIB-WL).

DESIGN: Open uncontrolled cohort study of obese male subjects with OSA in an SIB-WL.

SUBJECTS: Eighty-seven obese (body mass index =34.2+/-2.8 kg/m(2)) middle-aged (46.3+/-9.3 years) male subjects with symptomatic OSA (Epworth score 13.4+/-3.6; respiratory disturbance index (RDI) 46.0+/-23.1 events/h) completed the study.

RESULTS: At 6 months, there was significant weight loss (8.3+/-4.7 kg, P<0.0001), as well as a reduction in waist and neck circumference and sagittal height (all P<0.0001). These changes were accompanied by a reduction in OSA severity (RDI fell by 16.3+/-19.4 events/h and Epworth score by 4.5+/-4.6), both P<0.0001). There was no significant change to systolic (P=0.07) or diastolic blood pressure (P=0.87); however, there was a mild rise in resting heart rate (P<0.0001).

CONCLUSION: Moderate (approximately 10%) weight loss with SIB-WL results in improvement in OSA severity without increase in blood pressure in closely monitored OSA subjects.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (HTML) ↗

The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief